A Copper-Nitroxide Adduct Exhibiting Separate Single Crystal-to-Single Crystal Polymerization-Depolymerization and Spin Crossover Transitions

© 2016 American Chemical Society.A complex cascade of solid-state processes initiated by variation of temperature was found for the heterospin complex [Cu(hfac)2LMe/Et] formed in the reaction of copper(II) hexafluoroacetylacetonate [Cu(hfac)2] with stable nitronyl nitroxide 2-(1-methyl-3-ethyl-1H-pyrazol-4-yl)-4,4,5,5-tetramethyl-4,5-dihydro-1H-imidazole-3-oxide-1-oxyl (LMe/Et). The cooling of the compound below 260 K initiated a solid-state chemical reaction, which led to a depolymerization of chains and formation of a pair heterospin complex [Cu(hfac)2LMe/Et2][[Cu(hfac)2]3LMe/Et2]. Further decrease in temperature below 144 K led to a spin transition accompanied by a drastic decrease in the effective magnetic moment from 2.52 to 2.24 μB. When the compound was heated, the order of effects was reversed: at first, the magnetic moment abruptly increased, and then the molecular fragments of the pair cluster united into polymer chains. Two hysteresis loops correspond to this cascade of temperature-induced structural transformations on the experimental dependence μeff(T): one at high (T ' = 283 K and T " = 260 K) and the other at low (T= 161 K, T = 144 K) temperature. The spin transitions were also recorded for the [[Cu(hfac)2]3LBu/Et2] and [[Cu(hfac)2]5LBu/Et4] molecular complexes, which are models of the trinuclear fragment of the {[Cu(hfac)2]3LMe/Et2} pair cluster

Результаты открытого многоцентрового неинтервенционного исследования клинической эффективности и переносимости эторикоксиба при остеоартрите и неспецифической боли в спине с дополнительной оценкой влияния препарата на «центральные» проявления боли

The formation of chronic musculoskeletal pain (MSP) is a multifactorial process, in its pathogenesis mechanism of central sensitization (CS) plays an important role.Objective: to evaluate the effectiveness of etoricoxib at a dose of 60 mg per day in diseases accompanied by moderate/severe chronic MPS, with an additional analysis of the effect of this drug on the manifestations of CS.Patients and methods. An open observational study, 790 patients (71.6% women, mean age 54.5±13.0 years) with osteoarthritis and chronic nonspecific back pain received etoricoxib 60 mg/day for 2 weeks. The dynamics of pain, dysfunction, fatigue, sleep disturbances, general health assessment (GHA) on a numerical rating scale (NRS 0–10), as well as signs of CS according to part A of the CSI questionnaire were assessed.Results and discussion. After 2 weeks, the intensity of pain during movement, at rest and at night decreased on average by 58.8±24.1, 69.7±32.6 and 70.1±32.8% respectively; functional insufficiency by 58.2±22.5%, fatigue by 52.2±25.8%, GHA by 50.0±22.6%, sleep improvement by 54.3±25.8% was observed (p<0.001 for all parameters). There was a decrease in the CSI value by an average of 33.1±14.5% (p<0.001), as well as a decrease in the number of patients with highly probable CS (CSI ≥40) from 35.3 to 10.3% (p<0.001). No serious drug-related complications were recorded. The overall frequency of adverse reactions was 5.9%, with dyspepsia and hypertension being the most common.Conclusion. Etoricoxib is an effective and relatively safe treatment for chronic MSP. It reduces the severity of CS, one of the central mechanisms of the pathogenesis of chronic MSP.Формирование хронической скелетно-мышечной боли (СМБ) – многофакторный процесс, в патогенезе которого существенную роль играет механизм центральной сенситизации (ЦС).Цель исследования – оценка эффективности эторикоксиба в дозе 60 мг/сут при заболеваниях, сопровождающихся умеренно выраженной/выраженной хронической СМБ, с дополнительным анализом влияния этого препарата на проявления ЦС.Пациенты и методы. Было проведено открытое наблюдательное исследование, в котором 790 пациентов (71,6% женщин, средний возраст 54,5±13,0 лет) с остеоартритом и хронической неспецифической болью в спине в течение 2 нед получали эторикоксиб по 60 мг/сут. Оценивалась динамика боли, нарушения функции, усталости, расстройств сна, общей оценки состояния здоровья (ООСЗ) по числовой рейтинговой шкале (ЧРШ, 0–10), а также признаков ЦС по части А опросника CSI.Результаты и обсуждение. Через 2 нед интенсивность боли при движении, в покое и ночью снизилась в среднем соответственно на 58,8±24,1; 69,7±32,6 и 70,1±32,8%, функциональная недостаточность – на 58,2±22,5%, усталость – на 52,2±25,8%, ООСЗ – на 50,0±22,6%, наблюдалось улучшение сна на 54,3±25,8% (р<0,001 для всех параметров). Было отмечено снижение значения CSI в среднем на 33,1±14,5% (р<0,001), а также числа пациентов с высоковероятной ЦС (CSI≥40) с 35,3 до 10,3% (р<0,001). Не было зафиксировано серьезных лекарственных осложнений. Общая частота нежелательных реакций составила 5,9%, наиболее часто встречались диспепсия и артериальная гипертензия.Заключение. Эторикоксиб является эффективным и относительно безопасным средством для контроля хронической СМБ. Он снижает выраженность ЦС – одного из центральных механизмов патогенеза хронической СМБ

Contraception in premenopausal women

The article tells about methods of contraception for women in premenopausal age. Levonorgestrel intrauterine device (LNG-IUD) is a highly effective method of contraception in this age group. Locally acting levonorgestrel reduces the duration of bleeding during menstruation and has a therapeutic benefit in the treatment of endometrial hyperplasia

TOFISOPAM: PROSPECTS FOR NON-HORMONAL THERAPY OF NEURO-VEGETATIVE AND PSYCHO-EMOTIONAL DISORDERS ASSOCIATED WITH MENOPAUSAL SYNDROME

Despite the proven effect of menopausal hormone therapy on menopausal syndrome, a number of factors prevent perimenopausal women from receiving the treatment. The article is a review of literature on the possibility of non-hormonal treatment with tofisopam for neuro-vegetative and psycho-emotional disorders associated with climacteric syndrome. The article tells about the efficacy and safety of the drug taking into account its pharmacodynamic properties

THE COURSE FEATURES, DIAGNOSIS AND TREATMENT OF PLACENTAL INSUFFICIENCY IN VARICOSITY

Placental insufficiency (PI) is a major problem of modern perinatology. Chronic placental insufficiency (CPI) is observed in every third pregnant woman at high risk of perinatal pathology. Perinatal mortality reaches 60% in this group. We investigated the modern approaches to diagnosis, prevention and therapy of placental insufficiency, including during varicosity. We studied the efficacy of Phlebodia 600 in the combined therapy of patients with PI. Based on these findings we are recommend prevention of PI (by Phlebodia 600) for all pregnant women with varicose veins, on the basis of morphologically confirmed reduction of placentas compensatory reaction

USE OF GONADOTROPIN-RELEASING HORMONE AGONISTS IN TREATMENT OF RECURRENT PRE-MENSTRUAL ENDOMETRIAL HYPERPLASIA

This article presents modern insights into the pathogenesis of endometrium hyperplastic processes, matrix metalloproteinases and their tissue inhibitors, and their role in development of endometrium hyperplasia. A pathogenetic substantiation is given for use of Lucrin Depot, which affects the key molecular mechanisms of development of hyperplastic processes, with the objective of pharmacological correction of this patholog

GESTATIONAL DIABETUS MELLITUS AT A POPULATION LEVEL. MEDICINAL THERAPY OF THREATENING MISCARRIAGE AND CARBOHYDRATE METABOLISM (literature survey)

This article presents a literature survey on the pathogenesis of gestational diabetes mellitus and abnormal carbohydrate metabolism during pregnancy. Also, the effects of some medicinal drugs which may provoke hyperglycemia during pregnancy leading in turn to different perinatal and maternal complications are discussed

MEDULLARY THYROID CANCER AS PART OF MEN 2B SYNDROME. CASE REPORT

MEN 2B syndrome is a subtype of the multiple endocrine neoplasia type 2. It is characterized by the development of aggressive forms of medullary thyroid cancer at an early age, pheochromocytoma and hyperparathyroid syndrome. This article provides an own clinical observation of the patient with MEN 2B syndrome associated with a mutation in the proto-oncogene RET